Biotech Values

[iwfal]

CLDX -

So if I am reading this correctly they are saying that EGFRvIII positive status leads to longer survival which is completely the opposite of what CLDX/Dr. Sampson have claimed that being EGFRvIII positive is a highly poor prognostic factor for survival. I do not know enough about the science to judge who is right or if this was just an oddball journal article.

Oddball journal article. 79 patients and they ran a Cox Regression on 4 or 5 potential prognostics. Completely moronic. (vs the Pelloski paper cited by CLDX which is 650 or so and uses a much more sound methodology) That said:

1) One of my key areas of discomfort with CLDX is that they were strident in emphasizing the wonderfulness of their case matched trial comparator. Danger, danger! No case matched controlled trial with 17 patients is worth much of anything.

2) They have no randomized data and I haven't looked yet at all the historicals. So can't comment.

Note - one interesting piece of the paper you pointed to is that recurrent GBM typically does not have as much EGFRviii as the original tumor. This is important because one of the more interesting pieces of rindo data is that treated patients seem to clear EGFRviii upon recurrence. More research needed.

Clark